PRLD News and Press, Prelude Therapeutics Incorporated From 02/29/24

WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays Global Healthcare Conference in Miami, March 12-14, 2024. On Wedne...

2024-02-21 17:29:54 ET More on Prelude Therapeutics Prelude Therapeutics: Interesting Pipeline That Is Too Early To Warrant My Buy Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data Seeking Alpha’s Quant Rating on Prelude T...

2024-02-16 10:58:39 ET More on Prelude Therapeutics Prelude Therapeutics: Interesting Pipeline That Is Too Early To Warrant My Buy Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data Seeking Alpha’s Quant Rating on Prelude T...

2024-02-16 01:40:06 ET More on Prelude Therapeutics Prelude Therapeutics: Interesting Pipeline That Is Too Early To Warrant My Buy Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data Seeking Alpha’s Quant Rating on Prelude T...

First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND expected to be filed in first half and enter Phase 1 clinical trial in second half of 2024 ...

2024-02-05 05:07:24 ET Summary Prelude Therapeutics is a clinical-stage biopharma developing targeted therapies for different cancers. PRLD has three drugs in clinical testing, including a degrader of a protein involved in cell division and a CDK9 inhibitor. The company has a ...

2024-02-02 19:01:21 ET Summary Prelude Therapeutics once produced positive clinical data from a now abandoned program. The company's current lead candidates are PRT3789, a SMARCA2 inhibitor, and PRT2527, a CDK9 inhibitor, both in phase 1 trials. Both programs have early precli...

2023-12-16 13:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the biggest stories of the year has been the rise of AI in every industry. This trend will hit biotech stocks no less than any others. Already, cutting edge healthcare stocks ...

2023-12-11 09:53:54 ET More on Prelude Therapeutics Seeking Alpha’s Quant Rating on Prelude Therapeutics Historical earnings data for Prelude Therapeutics Financial information for Prelude Therapeutics For further details see: Prelude Therapeutics ...

WILMINGTON, Del., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced a private placement that the Company estimates will result in gross proc...